{"id":"NCT02492711","sponsor":"MacroGenics","briefTitle":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","officialTitle":"A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-24","primaryCompletion":"2021-08-11","completion":"2022-06-14","firstPosted":"2015-07-09","resultsPosted":"2022-11-23","lastUpdate":"2025-03-17"},"enrollment":624,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HER-2 Positive Breast Cancer","Metastatic Neoplasm"],"interventions":[{"type":"BIOLOGICAL","name":"Margetuximab","otherNames":["MGAH22","Margenza®"]},{"type":"BIOLOGICAL","name":"Trastuzumab","otherNames":["Herceptin®"]},{"type":"DRUG","name":"Physician's choice of chemotherapy.","otherNames":[]}],"arms":[{"label":"Margetuximab plus chemotherapy","type":"EXPERIMENTAL"},{"label":"Trastuzumab plus chemotherapy","type":"ACTIVE_COMPARATOR"},{"label":"Margetuximab Infusion Sub-study","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with trastuzumab plus chemotherapy.\n\nA non-randomized sub-study cohort of approximately 88 patients will be enrolled to evaluate the safety of a reduced margetuximab infusion rate in patients receiving margetuximab either as monotherapy or in combination with chemotherapy.","primaryOutcome":{"measure":"Progression-free Survival (PFS) as Determined by Independent Radiological Review.","timeFrame":"Tumor assessments are conducted every 6 weeks for the first 24 weeks and then every 24 weeks until progression of cancer, average 5 months.","effectByArm":[{"arm":"Margetuximab Plus Chemotherapy","deltaMin":5.8,"sd":null},{"arm":"Trastuzumab Plus Chemotherapy","deltaMin":4.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0334"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":6},"locations":{"siteCount":167,"countries":["United States","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Israel","Italy","Netherlands","Poland","Portugal","Puerto Rico","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["36332179","33480963"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":47,"n":264},"commonTop":["Fatigue","Nausea","Diarrhoea","Neutropenia","Anaemia"]}}